Reference curves for CD4 T-cell count response to combination antiretroviral therapy in HIV-1-infected treatment-naïve patients

V. Bouteloup; C. Sabin; A. Mocroft; L. Gras; N. Pantazis; V. Le Moing; A. d'Arminio Monforte; M. Mary-Krause; B. Roca; J. M. Miro; M. Battegay; N. Brockmeyer; J. Berenguer; P. Morlat; N. Obel; S. De Wit; G. Fätkenheuer; R. Zangerle; J. Ghosn; S. Pérez-Hoyos; M. Campbell; M. Prins; G. Chêne; L. Meyer; M. Dorrucci; C. Torti; R. Thiébaut; Giota Touloumi; Josiane Warszawski; François Dabis; Catherine Leport; Linda Wittkop; Peter Reiss; Ferdinand Wit; Heiner Bucher; Diana Gibb; Julia Del Amo; Claire Thorne; Ole Kirk; Christoph Stephan; Osamah Hamouda; Barbara Bartmeyer; Nikoloz Chkhartishvili; Antoni Noguera-Julian; Andrea Antinori; Luis Prieto; Pablo Rojo Conejo; Antoni Soriano-Arandes; Andri Rauch; Cristina Mussini; Pat Tookey; Jordi Casabona; Antonella Castagna; Tessa Deborah Konopnick; Tessa Goetghebuer; Anders Sönnerborg; Ramon Teira; Myriam Garrido; David Haerry; Dominique Costagliola; Antonella Castagna; Julia del Amo; Dorthe Raben; Ali Judd; Pablo Rojo Conejo; Diana Barger; Céline Colin; Christine Schwimmer; Monique Termote; Nina Friis-Møller; Jesper Kjaer; Dorthe Raben; Rikke Salbøl Brandt; Julia Bohlius; Heiner Bucher; Alessandro Cozzi-Lepri; François Dabis; Mary Anne Davies; Julia del Amo; David Dunn; Matthias Egger; Hansjakob Furrer; Marguerite Guiguet; Sophie Grabar; Ali Judd; Ole Kirk; Olivier Lambotte; Valériane Leroy; Sara Lodi; Sophie Matheron; Susana Monge; Fumiyo Nakagawa; Roger Paredes; Andrew Phillips; Massimo Puoti; Michael Schomaker; Colette Smit; Jonathan Sterne; Rodolphe Thiebaut

doi:10.1111/hiv.12389

Reference curves for CD4 T-cell count response to combination antiretroviral therapy in HIV-1-infected treatment-naïve patients

V. Bouteloup, C. Sabin, A. Mocroft, L. Gras, N. Pantazis, V. Le Moing, A. d'Arminio Monforte, M. Mary-Krause, B. Roca, J. M. Miro, M. Battegay, N. Brockmeyer, J. Berenguer, P. Morlat, N. Obel, S. De Wit, G. Fätkenheuer, R. Zangerle, J. Ghosn, S. Pérez-HoyosM. Campbell, M. Prins, G. Chêne, L. Meyer, M. Dorrucci, C. Torti, R. Thiébaut, Giota Touloumi, Josiane Warszawski, François Dabis, Catherine Leport, Linda Wittkop, Peter Reiss, Ferdinand Wit, Heiner Bucher, Diana Gibb, Julia Del Amo, Claire Thorne, Ole Kirk, Christoph Stephan, Osamah Hamouda, Barbara Bartmeyer, Nikoloz Chkhartishvili, Antoni Noguera-Julian, Andrea Antinori, Luis Prieto, Pablo Rojo Conejo, Antoni Soriano-Arandes, Andri Rauch, Cristina Mussini, Pat Tookey, Jordi Casabona, Antonella Castagna, Tessa Deborah Konopnick, Tessa Goetghebuer, Anders Sönnerborg, Ramon Teira, Myriam Garrido, David Haerry, Dominique Costagliola, Antonella Castagna, Julia del Amo, Dorthe Raben, Ali Judd, Pablo Rojo Conejo, Diana Barger, Céline Colin, Christine Schwimmer, Monique Termote, Nina Friis-Møller, Jesper Kjaer, Dorthe Raben, Rikke Salbøl Brandt, Julia Bohlius, Heiner Bucher, Alessandro Cozzi-Lepri, François Dabis, Mary Anne Davies, Julia del Amo, David Dunn, Matthias Egger, Hansjakob Furrer, Marguerite Guiguet, Sophie Grabar, Ali Judd, Ole Kirk, Olivier Lambotte, Valériane Leroy, Sara Lodi, Sophie Matheron, Susana Monge, Fumiyo Nakagawa, Roger Paredes, Andrew Phillips, Massimo Puoti, Michael Schomaker, Colette Smit, Jonathan Sterne, Rodolphe Thiebaut

Producció científica: Contribució a revista › Article › Recerca › Avaluat per experts

16 Cites (Scopus)

Resum

© 2016 British HIV Association Objectives: The aim of this work was to provide a reference for the CD4 T-cell count response in the early months after the initiation of combination antiretroviral therapy (cART) in HIV-1-infected patients. Methods: All patients in the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) cohort who were aged ≥ 18 years and started cART for the first time between 1 January 2005 and 1 January 2010 and who had at least one available measurement of CD4 count and a viral load ≤ 50 HIV-1 RNA copies/mL at 6 months (± 3 months) after cART initiation were included in the study. Unadjusted and adjusted references curves and predictions were obtained using quantile regressions. Results: A total of 28 992 patients were included in the study. The median CD4 T-cell count at treatment initiation was 249 [interquartile range (IQR) 150, 336] cells/μL. The median observed CD4 counts at 6, 9 and 12 months were 382 (IQR 256, 515), 402 (IQR 274, 543) and 420 (IQR 293, 565) cells/μL. The two main factors explaining the variation of CD4 count at 6 months were AIDS stage and CD4 count at cART initiation. A CD4 count increase of ≥ 100 cells/mL is generally required in order that patients stay ‘on track’ (i.e. with a CD4 count at the same percentile as when they started), with slightly higher gains required for those starting with CD4 counts in the higher percentiles. Individual predictions adjusted for factors influencing CD4 count were more precise. Conclusions: Reference curves aid the evaluation of the immune response early after antiretroviral therapy initiation that leads to viral control.

Idioma original	Anglès
Pàgines (de-a)	33-44
Revista	HIV Medicine
Volum	18
Número	1
DOIs	https://doi.org/10.1111/hiv.12389
Estat de la publicació	Publicada - 1 de gen. 2017

SDG de les Nacions Unides

Aquest resultat contribueix als següents objectius de desenvolupament sostenible.

Accés al document

10.1111/hiv.12389

Com citar-ho

Bouteloup, V., Sabin, C., Mocroft, A., Gras, L., Pantazis, N., Le Moing, V., d'Arminio Monforte, A., Mary-Krause, M., Roca, B., Miro, J. M., Battegay, M., Brockmeyer, N., Berenguer, J., Morlat, P., Obel, N., De Wit, S., Fätkenheuer, G., Zangerle, R., Ghosn, J., ... Thiebaut, R. (2017). Reference curves for CD4 T-cell count response to combination antiretroviral therapy in HIV-1-infected treatment-naïve patients. HIV Medicine, 18(1), 33-44. https://doi.org/10.1111/hiv.12389

@article{9e27f7daa7fd4469b715c58deeb6d8c0,

title = "Reference curves for CD4 T-cell count response to combination antiretroviral therapy in HIV-1-infected treatment-na{\"i}ve patients",

abstract = "{\textcopyright} 2016 British HIV Association Objectives: The aim of this work was to provide a reference for the CD4 T-cell count response in the early months after the initiation of combination antiretroviral therapy (cART) in HIV-1-infected patients. Methods: All patients in the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) cohort who were aged ≥ 18 years and started cART for the first time between 1 January 2005 and 1 January 2010 and who had at least one available measurement of CD4 count and a viral load ≤ 50 HIV-1 RNA copies/mL at 6 months (± 3 months) after cART initiation were included in the study. Unadjusted and adjusted references curves and predictions were obtained using quantile regressions. Results: A total of 28 992 patients were included in the study. The median CD4 T-cell count at treatment initiation was 249 [interquartile range (IQR) 150, 336] cells/μL. The median observed CD4 counts at 6, 9 and 12 months were 382 (IQR 256, 515), 402 (IQR 274, 543) and 420 (IQR 293, 565) cells/μL. The two main factors explaining the variation of CD4 count at 6 months were AIDS stage and CD4 count at cART initiation. A CD4 count increase of ≥ 100 cells/mL is generally required in order that patients stay {\textquoteleft}on track{\textquoteright} (i.e. with a CD4 count at the same percentile as when they started), with slightly higher gains required for those starting with CD4 counts in the higher percentiles. Individual predictions adjusted for factors influencing CD4 count were more precise. Conclusions: Reference curves aid the evaluation of the immune response early after antiretroviral therapy initiation that leads to viral control.",

keywords = "antiretroviral treatment monitoring, CD4 response, HIV monitoring, longitudinal data",

author = "V. Bouteloup and C. Sabin and A. Mocroft and L. Gras and N. Pantazis and {Le Moing}, V. and {d'Arminio Monforte}, A. and M. Mary-Krause and B. Roca and Miro, {J. M.} and M. Battegay and N. Brockmeyer and J. Berenguer and P. Morlat and N. Obel and {De Wit}, S. and G. F{\"a}tkenheuer and R. Zangerle and J. Ghosn and S. P{\'e}rez-Hoyos and M. Campbell and M. Prins and G. Ch{\^e}ne and L. Meyer and M. Dorrucci and C. Torti and R. Thi{\'e}baut and Giota Touloumi and Josiane Warszawski and Fran{\c c}ois Dabis and Catherine Leport and Linda Wittkop and Peter Reiss and Ferdinand Wit and Heiner Bucher and Diana Gibb and Amo, {Julia Del} and Claire Thorne and Ole Kirk and Christoph Stephan and Osamah Hamouda and Barbara Bartmeyer and Nikoloz Chkhartishvili and Antoni Noguera-Julian and Andrea Antinori and Luis Prieto and Conejo, {Pablo Rojo} and Antoni Soriano-Arandes and Andri Rauch and Cristina Mussini and Pat Tookey and Jordi Casabona and Antonella Castagna and {Deborah Konopnick}, Tessa and Tessa Goetghebuer and Anders S{\"o}nnerborg and Ramon Teira and Myriam Garrido and David Haerry and Dominique Costagliola and Antonella Castagna and {del Amo}, Julia and Dorthe Raben and Ali Judd and Conejo, {Pablo Rojo} and Diana Barger and C{\'e}line Colin and Christine Schwimmer and Monique Termote and Nina Friis-M{\o}ller and Jesper Kjaer and Dorthe Raben and Brandt, {Rikke Salb{\o}l} and Julia Bohlius and Heiner Bucher and Alessandro Cozzi-Lepri and Fran{\c c}ois Dabis and Davies, {Mary Anne} and {del Amo}, Julia and David Dunn and Matthias Egger and Hansjakob Furrer and Marguerite Guiguet and Sophie Grabar and Ali Judd and Ole Kirk and Olivier Lambotte and Val{\'e}riane Leroy and Sara Lodi and Sophie Matheron and Susana Monge and Fumiyo Nakagawa and Roger Paredes and Andrew Phillips and Massimo Puoti and Michael Schomaker and Colette Smit and Jonathan Sterne and Rodolphe Thiebaut",

year = "2017",

month = jan,

day = "1",

doi = "10.1111/hiv.12389",

language = "English",

volume = "18",

pages = "33--44",

journal = "HIV Medicine",

issn = "1464-2662",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "1",

}

Bouteloup, V, Sabin, C, Mocroft, A, Gras, L, Pantazis, N, Le Moing, V, d'Arminio Monforte, A, Mary-Krause, M, Roca, B, Miro, JM, Battegay, M, Brockmeyer, N, Berenguer, J, Morlat, P, Obel, N, De Wit, S, Fätkenheuer, G, Zangerle, R, Ghosn, J, Pérez-Hoyos, S, Campbell, M, Prins, M, Chêne, G, Meyer, L, Dorrucci, M, Torti, C, Thiébaut, R, Touloumi, G, Warszawski, J, Dabis, F, Leport, C, Wittkop, L, Reiss, P, Wit, F, Bucher, H, Gibb, D, Amo, JD, Thorne, C, Kirk, O, Stephan, C, Hamouda, O, Bartmeyer, B, Chkhartishvili, N, Noguera-Julian, A, Antinori, A, Prieto, L, Conejo, PR, Soriano-Arandes, A, Rauch, A, Mussini, C, Tookey, P, Casabona, J, Castagna, A, Deborah Konopnick, T, Goetghebuer, T, Sönnerborg, A, Teira, R, Garrido, M, Haerry, D, Costagliola, D, Castagna, A, del Amo, J, Raben, D, Judd, A, Conejo, PR, Barger, D, Colin, C, Schwimmer, C, Termote, M, Friis-Møller, N, Kjaer, J, Raben, D, Brandt, RS, Bohlius, J, Bucher, H, Cozzi-Lepri, A, Dabis, F, Davies, MA, del Amo, J, Dunn, D, Egger, M, Furrer, H, Guiguet, M, Grabar, S, Judd, A, Kirk, O, Lambotte, O, Leroy, V, Lodi, S, Matheron, S, Monge, S, Nakagawa, F, Paredes, R, Phillips, A, Puoti, M, Schomaker, M, Smit, C, Sterne, J & Thiebaut, R 2017, 'Reference curves for CD4 T-cell count response to combination antiretroviral therapy in HIV-1-infected treatment-naïve patients', HIV Medicine, vol. 18, núm. 1, pàg. 33-44. https://doi.org/10.1111/hiv.12389

TY - JOUR

T1 - Reference curves for CD4 T-cell count response to combination antiretroviral therapy in HIV-1-infected treatment-naïve patients

AU - Bouteloup, V.

AU - Sabin, C.

AU - Mocroft, A.

AU - Gras, L.

AU - Pantazis, N.

AU - Le Moing, V.

AU - d'Arminio Monforte, A.

AU - Mary-Krause, M.

AU - Roca, B.

AU - Miro, J. M.

AU - Battegay, M.

AU - Brockmeyer, N.

AU - Berenguer, J.

AU - Morlat, P.

AU - Obel, N.

AU - De Wit, S.

AU - Fätkenheuer, G.

AU - Zangerle, R.

AU - Ghosn, J.

AU - Pérez-Hoyos, S.

AU - Campbell, M.

AU - Prins, M.

AU - Chêne, G.

AU - Meyer, L.

AU - Dorrucci, M.

AU - Torti, C.

AU - Thiébaut, R.

AU - Touloumi, Giota

AU - Warszawski, Josiane

AU - Dabis, François

AU - Leport, Catherine

AU - Wittkop, Linda

AU - Reiss, Peter

AU - Wit, Ferdinand

AU - Bucher, Heiner

AU - Gibb, Diana

AU - Amo, Julia Del

AU - Thorne, Claire

AU - Kirk, Ole

AU - Stephan, Christoph

AU - Hamouda, Osamah

AU - Bartmeyer, Barbara

AU - Chkhartishvili, Nikoloz

AU - Noguera-Julian, Antoni

AU - Antinori, Andrea

AU - Prieto, Luis

AU - Conejo, Pablo Rojo

AU - Soriano-Arandes, Antoni

AU - Rauch, Andri

AU - Mussini, Cristina

AU - Tookey, Pat

AU - Casabona, Jordi

AU - Castagna, Antonella

AU - Deborah Konopnick, Tessa

AU - Goetghebuer, Tessa

AU - Sönnerborg, Anders

AU - Teira, Ramon

AU - Garrido, Myriam

AU - Haerry, David

AU - Costagliola, Dominique

AU - Castagna, Antonella

AU - del Amo, Julia

AU - Raben, Dorthe

AU - Judd, Ali

AU - Conejo, Pablo Rojo

AU - Barger, Diana

AU - Colin, Céline

AU - Schwimmer, Christine

AU - Termote, Monique

AU - Friis-Møller, Nina

AU - Kjaer, Jesper

AU - Raben, Dorthe

AU - Brandt, Rikke Salbøl

AU - Bohlius, Julia

AU - Bucher, Heiner

AU - Cozzi-Lepri, Alessandro

AU - Dabis, François

AU - Davies, Mary Anne

AU - del Amo, Julia

AU - Dunn, David

AU - Egger, Matthias

AU - Furrer, Hansjakob

AU - Guiguet, Marguerite

AU - Grabar, Sophie

AU - Judd, Ali

AU - Kirk, Ole

AU - Lambotte, Olivier

AU - Leroy, Valériane

AU - Lodi, Sara

AU - Matheron, Sophie

AU - Monge, Susana

AU - Nakagawa, Fumiyo

AU - Paredes, Roger

AU - Phillips, Andrew

AU - Puoti, Massimo

AU - Schomaker, Michael

AU - Smit, Colette

AU - Sterne, Jonathan

AU - Thiebaut, Rodolphe

PY - 2017/1/1

Y1 - 2017/1/1

N2 - © 2016 British HIV Association Objectives: The aim of this work was to provide a reference for the CD4 T-cell count response in the early months after the initiation of combination antiretroviral therapy (cART) in HIV-1-infected patients. Methods: All patients in the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) cohort who were aged ≥ 18 years and started cART for the first time between 1 January 2005 and 1 January 2010 and who had at least one available measurement of CD4 count and a viral load ≤ 50 HIV-1 RNA copies/mL at 6 months (± 3 months) after cART initiation were included in the study. Unadjusted and adjusted references curves and predictions were obtained using quantile regressions. Results: A total of 28 992 patients were included in the study. The median CD4 T-cell count at treatment initiation was 249 [interquartile range (IQR) 150, 336] cells/μL. The median observed CD4 counts at 6, 9 and 12 months were 382 (IQR 256, 515), 402 (IQR 274, 543) and 420 (IQR 293, 565) cells/μL. The two main factors explaining the variation of CD4 count at 6 months were AIDS stage and CD4 count at cART initiation. A CD4 count increase of ≥ 100 cells/mL is generally required in order that patients stay ‘on track’ (i.e. with a CD4 count at the same percentile as when they started), with slightly higher gains required for those starting with CD4 counts in the higher percentiles. Individual predictions adjusted for factors influencing CD4 count were more precise. Conclusions: Reference curves aid the evaluation of the immune response early after antiretroviral therapy initiation that leads to viral control.

AB - © 2016 British HIV Association Objectives: The aim of this work was to provide a reference for the CD4 T-cell count response in the early months after the initiation of combination antiretroviral therapy (cART) in HIV-1-infected patients. Methods: All patients in the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) cohort who were aged ≥ 18 years and started cART for the first time between 1 January 2005 and 1 January 2010 and who had at least one available measurement of CD4 count and a viral load ≤ 50 HIV-1 RNA copies/mL at 6 months (± 3 months) after cART initiation were included in the study. Unadjusted and adjusted references curves and predictions were obtained using quantile regressions. Results: A total of 28 992 patients were included in the study. The median CD4 T-cell count at treatment initiation was 249 [interquartile range (IQR) 150, 336] cells/μL. The median observed CD4 counts at 6, 9 and 12 months were 382 (IQR 256, 515), 402 (IQR 274, 543) and 420 (IQR 293, 565) cells/μL. The two main factors explaining the variation of CD4 count at 6 months were AIDS stage and CD4 count at cART initiation. A CD4 count increase of ≥ 100 cells/mL is generally required in order that patients stay ‘on track’ (i.e. with a CD4 count at the same percentile as when they started), with slightly higher gains required for those starting with CD4 counts in the higher percentiles. Individual predictions adjusted for factors influencing CD4 count were more precise. Conclusions: Reference curves aid the evaluation of the immune response early after antiretroviral therapy initiation that leads to viral control.

KW - antiretroviral treatment monitoring

KW - CD4 response

KW - HIV monitoring

KW - longitudinal data

U2 - 10.1111/hiv.12389

DO - 10.1111/hiv.12389

M3 - Article

SN - 1464-2662

VL - 18

SP - 33

EP - 44

JO - HIV Medicine

JF - HIV Medicine

IS - 1

ER -

Reference curves for CD4 T-cell count response to combination antiretroviral therapy in HIV-1-infected treatment-naïve patients

Resum

SDG de les Nacions Unides

Accés al document

Fingerprint

Com citar-ho